ArticleCell reports. Medicine2025

CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma.

Minghao Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.